1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

Summary

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Risperdal (risperidone; Janssen) is a potent 5-HT2A/D2 receptor antagonist, with a higher relative affinity for 5-HT2A over D2 and D3 receptors. Risperdal was first approved by the FDA in 1993 and was the first antipsychotic approved after clozapine. After establishing a solid claim of the atypical antipsychotics market throughout the late 1990s and early 2000s, the development of long-acting injectable Risperdal Consta has helped the brand survive patent expirations to older formulations.

Scope

- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Risperdal including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Risperdal for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Risperdal performance
- Obtain sales forecast for Risperdal from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table Of Contents

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Symptoms 13
4 Disease Management 15
4.1 Diagnosis 15
4.1.1 Subjective Assessments 16
4.1.2 Disease Subtypes 17
4.2 Treatment Overview 20
4.2.1 Treatment of Acute Agitation Associated with Schizophrenia 22
4.2.2 Maintenance Treatment of Schizophrenia 23
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26
6 Risperdal (risperidone) 28
6.1 Overview 28
6.2 Efficacy 30
6.3 Safety 30
6.4 SWOT Analysis 31
6.5 Forecast 31
7 Appendix 32
7.1 Bibliography 32
7.2 Abbreviations 35
7.3 Methodology 36
7.4 Forecasting Methodology 36
7.4.1 Diagnosis and Treatment Rates 36
7.4.2 Adherence Rates 37
7.4.3 General Pricing Assumptions 37
7.4.4 Drug Assumptions 39
7.4.5 Generic Erosion 39
7.5 Key Opinion Leaders 40
7.6 About the Authors 41
7.6.1 Author 41
7.6.2 Reviewers 41
7.6.3 Global Head of Healthcare 42
7.7 About GlobalData 43
7.8 Disclaimer 43

1.1 List of Tables

Table 1: Symptom Clusters of Schizophrenia 14
Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis 17
Table 3: Development-Based Classification of Antipsychotic Drugs 20
Table 4: Receptor Binding Profiles of Atypical Antipsychotics 21
Table 5: Guidelines for the Treatment of Schizophrenia 22
Table 6: Leading Branded Treatments for Schizophrenia, 2013 27
Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014 27
Table 8: Product Profile - Risperdal 29
Table 9: Risperdal SWOT Analysis, 2013 31
Table 10: Global Sales Forecast ($m) for Risperdal, 2012-2022 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Emesis (Vomiting) Global Clinical Trials Review, H2, 2016

Emesis (Vomiting) Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • November 2016
  • by GlobalData

Emesis (Vomiting) Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Emesis (Vomiting) Global Clinical Trials Review, H2, 2016" provides an overview of Emesis (Vomiting) ...

Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TNS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014 - 2025

Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TNS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • December 2016
  • by Grand View Research

The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated to drive the market growth ...

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...


Download Unlimited Documents from Trusted Public Sources

Dysfunction Drug Market in Sweden

  • March 2017
    7 pages
  • Dysfunction Dru...  

    Therapy  

  • Sweden  

View report >

Therapy Market in the US

  • March 2017
    253 pages
  • Therapy  

    Anti-Infective  

    Hormone  

  • United States  

View report >

Therapy Market in the US

  • March 2017
    253 pages
  • Therapy  

    Anti-Infective  

    Hormone  

  • United States  

View report >

Related Market Segments :

Antipsychotic
Therapy
Psychotic Disorder

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.